Inactive Instrument

Highlights Alterity Therapeutics Ltd Australian S.E.

Equities

AU000000PBT9

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

ADRs End Lower, Purple Biotech Ltd. Declines 29%	Apr. 16	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	Apr. 11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	Apr. 10	DJ
Top Midday Gainers	Apr. 10	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	Mar. 25	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	Feb. 28	CI
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	CI
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease	Dec. 04	CI
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy	Nov. 27	CI
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy	Nov. 08	CI
Alterity Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Alterity Therapeutics Says it Secured European Patent Covering Neurodegenerative Disease Drug Candidates	23-08-23	MT
Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's	23-08-23	CI
Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study	23-07-26	CI
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder	23-05-30	CI
Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy	23-05-10	CI
Alterity Therapeutics Presents Promising Wearable Sensor Data from the Biomarkers of Progression in Multiple System	23-04-26	CI
Alterity Therapeutics Limited Doses the First Participant in the U.S. in Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy	23-03-15	CI
Alterity Therapeutics Limited Announces a Licensing Agreement for the New Patent and a Sub-Licensing Agreement for PBT2	23-03-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alterity Therapeutics Ltd Australian S.E.

Equities

AU000000PBT9

Highlights

Filters